YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway

British Journal of Pharmacology

Volumn 155, Issue 4, 2008, Pages 505-513

  Wu, S Y ^a   Pan, S L ^a   Chen, T H ^a   Liao, C H ^a   Huang, D Y ^a   Guh, J H ^a   Chang, Y L ^a   Kuo, S C ^b   Lee, F Y ^c   Teng, C M ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Yung Shin Pharmaceutical Industry Co Ltd   (Taiwan)

Author keywords

Apoptosis; JNK; Renal cancer; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 8; FAS ANTIGEN; FAS LIGAND; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, RENAL CELL; CASPASE 3; CASPASE 8; CHROMATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; FAS LIGAND PROTEIN; G1 PHASE; HUMANS; INDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION;

EID: 53849131648     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.292     Document Type: Article

References (32)

1. Boatright KM, Salvesen GS (2003). Mechanisms of caspase activation. Curr Opin Cell Biol 15: 725-731.
2. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS et al. (2001). Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61: 947-954.
3. Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, Koretzky GA et al. (1998b). The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol 160: 134-144.
4. Faris M, Latinis KM, Kempiak SJ, Koretzky GA, Nel A (1998a). Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol Cell Biol 18: 5414-5424.
5. Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, Santos-Beneit AM et al. (2004). Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 200: 353-365.
6. Gajate C, Fonteriz RI, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, Modolell M et al. (2000). Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 85: 674-682.
7. Garay M, Gaarde W, Monia BP, Nero P, Cioffi CL (2000). Inhibition of hypoxia/reoxygenation-induced apoptosis by an antisense oligonucleotide targeted to JNK1 in human kidney cells. Biochem Pharmacol 59: 1033-1043.
8. Godley PA, Taylor M (2001). Renal cell carcinoma. Curr Opin Oncol 7: 199-203.
9. Green DR, Kroemer G (2004). The pathophysiology of mitochondrial cell death. Science 305: 626-629.
10. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S (2005). c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391.
11. Huang YT, Pan SL, Guh JH, Chang YL, Lee FY, Kuo SC et al. (2005). YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 4: 1628-1635.
12. Hwang TL, Wu CC, Guh JH, Teng CM (2003). Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway. Biochem Pharmacol 66: 149-156.
13. Jin N, Hatton N, Swartz DR, Xia X, Harrington MA, Larsen SH et al. (2000). Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol 23: 593-601.
14. Kanda H, Miura M (2004). Regulatory roles of JNK in programmed cell death. J Biochem (Tokyo) 136: 1-6.
15. Kim WY, Kaelin WG (2004). Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004.
16. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM (1994). YC-1, a novel activator of platelet guanylate cyclase. Blood 84: 4226-4233.
17. Kunz M, Ibrahim S, Koczan D, Thiesen HJ, Köhler HJ, Acker T et al. (2001). Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ 12: 137-145.
18. Liu J, Lin A (2005). Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15: 36-42.
19. Minet E, Michel G, Mottet D, Piret JP, Barbieux A, Raes M et al. (2001). c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res 265: 114-124.
20. Pan SL, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM (2004). YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovasc Res 61: 152-158.
21. Pan SL, Guh JH, Peng CY, Wang SW, Chang YL, Cheng FC et al. (2005). YC-1 [3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther 314: 35-42.
22. Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M (2005). Immunotherapy in metastatic renal cell carcinoma. World J Urol 23: 196-201.
23. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P (2004). Toxic proteins released from mitochondria in cell death. Oncogene 23: 2861-2874.
24. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687.
25. Seko Y, Takahashi N, Tobe K, Kadowaki T, Yazaki Y (1997). Hypoxia and hypoxia/reoxygenation activate p65PAK, p38 mitogen-activated protein kinase (MAPK), and stress-activated protein kinase (SAPK) in cultured rat cardiac myocytes. Biochem Biophys Res Commun 239: 840-844.
26. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH et al. (2007). YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26: 3941-3951.
27. Thorburn A (2004). Death receptor-induced cell killing. Cell Signal 16: 139-144.
28. Wang SW, Pan SL, Guh JH, Chen HL, Huang DM, Chang YL et al. (2005). YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 312: 917-925.
29. Willis S, Day CL, Hinds MG, Huang DC (2003). The Bcl-2-regulated apoptotic pathway. J Cell Sci 116: 4053-4056.
30. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM (1995). YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116: 1973-1978.
31. Yeo EJ, Chun YS, Park JW (2004). New anticancer strategies targeting HIF-1. Biochem Pharmacol 68: 1061-1069.
32. Yin XM (2000). Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res 10: 161-167.